Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex® 600mg Extended-Release tablets.
Mucinex® 600mg Extended-Release tablets (Guaifenesin 600mg Extended-Release Tablets), an expectorant indicated to relieve chest congestion and make coughs more productive, had sales of approximately $135 million through food, drug and mass merchandisers for the last 12 months.
Perrigo's Chairman and CEO Joseph C. Papa stated, "This re-launch is representative of the Perrigo team's abilities to overcome challenging circumstances presented by this product's complex formulation. The team worked diligently to validate and achieve consistency in producing commercial production quantities required to bring this product back to market. This is another excellent example of Perrigo's investment and commitment to making quality healthcare more affordable for our customers."
Remote interpreting raises concerns about communication quality in healthcare